FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016346802> ?p ?o ?g. }

• W2016346802 endingPage "763" @default.
• W2016346802 startingPage "756" @default.
• W2016346802 abstract "There is an emerging consensus on conversion from calcineurin inhibitor (CNI)-based regimens to proliferation signal inhibitor (PSI)-based protocols for the prevention of a progressive decline in graft function due to CNI toxicity. Thirty-one primary renal transplant recipients within 17–48 years of age (mean, 32.2 ± 1.6) were enrolled in this dual-center study. Eligible patients had a baseline (pre-engraftment) biopsy and completed at least 12 months of follow-up with deteriorating graft function indicative of chronic CNI toxicity with or without nonspecific interstitial fibrosis/tubular atrophy (IF/TA) on a biopsy specimen. A fast conversion protocol, being defined as a 50% initial reduction followed by complete withdrawal of CNI drug within 2 weeks of introducing rapamycin was performed in all patients. A sirolimus (SRL) loading dose was not prescribed; all subjects directly received maintenance (2–5 mg/d) doses of the drug. The primary endpoint of this study was assessement of renal function using cGFR and renal histology by protocol biopsy at 1 year after conversion. The mean follow-up after conversion was 21.6 months. The difference between cGFR before compared with cGFR after 12 months after conversion (40.8 ± 2.36 mL/min vs 55.7 ± 3.6 mL/min; P < .000) and at the last follow-up (40.8 ± 2.36 mL/min vs 53.8 ± 2.96 mL/min; P < .000) was significant. The mean IF/TA with glomerulosclerosis and chronic vasculopathy scores of biopsy specimens at baseline, during conversion, and at 12 months of the study were 2.25 ± 0.3, 3.30 ± 0.24, and 3.0 ± 0.30, respectively. The change in scores was indicative of mild progression; however, the difference was not significant. IF/TA, glomerulosclerosis, and chronic vasculopathy scores improved in 8 (30%) subjects, remained unchanged in 11 (42%) and worsened in 7 (28%) after 1 year of SRL therapy. After conversion there was no patient or graft loss in this group. Moreover, SCr and GFR improved in 21 or 29 patients (72%), remained stable in 4 (14%), and decreased in 4 (14%) patients. The predictors of successful conversion in our study were GFR ≥ 40.6 mL/min, SCr ≤ 2.34 mg/dL, and histological allograft damage score ≤3. SRL-MPA/MMF-ST combination may be a good therapeutic strategy against chronic CNI toxicity, particularly for patients whose conversion biopsy specimens demonstrated mild IF/TA, glomerulosclerosis, and chronic vasculopathy scores (≤3.1 ± 0.3)." @default.
• W2016346802 created "2016-06-24" @default.
• W2016346802 creator A5020478046 @default.
• W2016346802 creator A5023133596 @default.
• W2016346802 creator A5026768763 @default.
• W2016346802 creator A5028949314 @default.
• W2016346802 creator A5039523407 @default.
• W2016346802 creator A5050634707 @default.
• W2016346802 creator A5075701714 @default.
• W2016346802 creator A5084072493 @default.
• W2016346802 creator A5086206860 @default.
• W2016346802 creator A5086561957 @default.
• W2016346802 date "2009-03-01" @default.
• W2016346802 modified "2023-09-27" @default.
• W2016346802 title "Late Conversion From Calcineurin Inhibitor–Based to Sirolimus-Based Immunosuppression Due to Chronic Toxicity: A Prospective Study With Protocol Biopsy Amendment" @default.
• W2016346802 cites W111059538 @default.
• W2016346802 cites W1966532219 @default.
• W2016346802 cites W1973645636 @default.
• W2016346802 cites W1988652338 @default.
• W2016346802 cites W1996950371 @default.
• W2016346802 cites W2023916742 @default.
• W2016346802 cites W2036313386 @default.
• W2016346802 cites W2037182741 @default.
• W2016346802 cites W2058640787 @default.
• W2016346802 cites W2079955997 @default.
• W2016346802 cites W2109101651 @default.
• W2016346802 cites W2112917982 @default.
• W2016346802 cites W2124662062 @default.
• W2016346802 cites W2124720938 @default.
• W2016346802 cites W2138620116 @default.
• W2016346802 cites W2139609632 @default.
• W2016346802 cites W2169639894 @default.
• W2016346802 cites W4231543135 @default.
• W2016346802 doi "https://doi.org/10.1016/j.transproceed.2009.01.044" @default.
• W2016346802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19328973" @default.
• W2016346802 hasPublicationYear "2009" @default.
• W2016346802 type Work @default.
• W2016346802 sameAs 2016346802 @default.
• W2016346802 citedByCount "5" @default.
• W2016346802 countsByYear W20163468022012 @default.
• W2016346802 countsByYear W20163468022016 @default.
• W2016346802 countsByYear W20163468022021 @default.
• W2016346802 crossrefType "journal-article" @default.
• W2016346802 hasAuthorship W2016346802A5020478046 @default.
• W2016346802 hasAuthorship W2016346802A5023133596 @default.
• W2016346802 hasAuthorship W2016346802A5026768763 @default.
• W2016346802 hasAuthorship W2016346802A5028949314 @default.
• W2016346802 hasAuthorship W2016346802A5039523407 @default.
• W2016346802 hasAuthorship W2016346802A5050634707 @default.
• W2016346802 hasAuthorship W2016346802A5075701714 @default.
• W2016346802 hasAuthorship W2016346802A5084072493 @default.
• W2016346802 hasAuthorship W2016346802A5086206860 @default.
• W2016346802 hasAuthorship W2016346802A5086561957 @default.
• W2016346802 hasConcept C126322002 @default.
• W2016346802 hasConcept C126894567 @default.
• W2016346802 hasConcept C128057223 @default.
• W2016346802 hasConcept C141071460 @default.
• W2016346802 hasConcept C159641895 @default.
• W2016346802 hasConcept C168563851 @default.
• W2016346802 hasConcept C203092338 @default.
• W2016346802 hasConcept C2775934546 @default.
• W2016346802 hasConcept C2777921159 @default.
• W2016346802 hasConcept C2780252810 @default.
• W2016346802 hasConcept C2780306776 @default.
• W2016346802 hasConcept C2911091166 @default.
• W2016346802 hasConcept C29730261 @default.
• W2016346802 hasConcept C71924100 @default.
• W2016346802 hasConceptScore W2016346802C126322002 @default.
• W2016346802 hasConceptScore W2016346802C126894567 @default.
• W2016346802 hasConceptScore W2016346802C128057223 @default.
• W2016346802 hasConceptScore W2016346802C141071460 @default.
• W2016346802 hasConceptScore W2016346802C159641895 @default.
• W2016346802 hasConceptScore W2016346802C168563851 @default.
• W2016346802 hasConceptScore W2016346802C203092338 @default.
• W2016346802 hasConceptScore W2016346802C2775934546 @default.
• W2016346802 hasConceptScore W2016346802C2777921159 @default.
• W2016346802 hasConceptScore W2016346802C2780252810 @default.
• W2016346802 hasConceptScore W2016346802C2780306776 @default.
• W2016346802 hasConceptScore W2016346802C2911091166 @default.
• W2016346802 hasConceptScore W2016346802C29730261 @default.
• W2016346802 hasConceptScore W2016346802C71924100 @default.
• W2016346802 hasIssue "2" @default.
• W2016346802 hasLocation W20163468021 @default.
• W2016346802 hasLocation W20163468022 @default.
• W2016346802 hasOpenAccess W2016346802 @default.
• W2016346802 hasPrimaryLocation W20163468021 @default.
• W2016346802 hasRelatedWork W2014603468 @default.
• W2016346802 hasRelatedWork W2029342078 @default.
• W2016346802 hasRelatedWork W2053110560 @default.
• W2016346802 hasRelatedWork W2059522950 @default.
• W2016346802 hasRelatedWork W2127860995 @default.
• W2016346802 hasRelatedWork W2148950609 @default.
• W2016346802 hasRelatedWork W2328872699 @default.
• W2016346802 hasRelatedWork W2330154650 @default.
• W2016346802 hasRelatedWork W2548660892 @default.
• W2016346802 hasRelatedWork W4205643111 @default.
• W2016346802 hasVolume "41" @default.
• W2016346802 isParatext "false" @default.

• next